Papers/PMID:42123439
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.
International journal of molecular sciences2026The record
3 findings drawn from this paper, on 1 compound across 3 endpoints.
What it reported
How to read these marksWhat moved
3 findings
curcumin — increases total antioxidant capacity
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×2“TAS levels were significantly higher in the curcumin group than in the placebo group (1.85 [1.74–1.95] vs. 1.65 [1.55–1.79], p < 0.001), with a large effect size ( r = 0.72, 95% CI: 0.61–0.81).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Curcumin 1500 mg/day orally for 12 months
- Population
- Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months; total antioxidant status reported in micromol trolox equivalent/L
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry funded
curcumin — decreases malondialdehyde (circulating)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×4“Conversely, MDA levels, a marker of lipid peroxidation, were significantly lower in the curcumin group compared with placebo (1.29 [1.05–1.58] vs. 2.45 [2.14–2.77], p < 0.001), corresponding to a large effect size ( r = 0.85, 95% CI: 0.77–0.91).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Curcumin 1500 mg/day orally for 12 months
- Population
- Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry funded
curcumin — decreases interleukin-6 concentration
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×3“Median IL-6 levels were markedly lower in the curcumin group than in the placebo group (5.50 [4.39–9.00] vs. 13.69 [11.27–15.65], p < 0.001), with a large effect size ( r = 0.78, 95% CI: 0.68–0.86).”
Quoted verbatim from Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- Curcumin 1500 mg/day orally for 12 months
- Population
- Adults with type 2 diabetes mellitus and obesity (n=114 randomised); secondary endpoint; between-group comparison at 12 months
Curcumin Supplementation Reduces Inflammation, Neutrophil-to-Lymphocyte Ratio (NLR), and Antioxidant Status in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial.2026PMID:42123439Industry funded